Clinical trial NCT06512766: a Retrospective Study on the Systemic Treatment of LPP and FFA
Official title: Cicatricial Alopecia: a Retrospective Study on the Systemic Treatment of Lichen Planopilaris and Frontal Fibrosing Alopecia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cicatricial Alopecia
Lichen Planopilaris
Lichen Plano-Pilaris
Frontal Fibrosing Alopecia
Hair Diseases
Scarring Alopecia
Hair Loss/Baldness
Keywords: Systemic treatment
Lead sponsor: Erasmus Medical Center
Sponsor class: OTHER
First posted: 2024-07-22
Enrollment: 315
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients diagnosed with International Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) diagnosis: L66 cicatricial alopecia, between July 2016 and July 2022, from the Department of Dermatology, Erasmus MC University Medical Center, were included.

Brief summary: This retrospective study aims to assess the effectiveness of systemic treatments for lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) in patients treated at the Erasmus MC University Medical Center. LPP and FFA are chronic inflammatory hair disorders leading to irreversible hair loss. The study evaluates treatment responses to systemic medications, including hydroxychloroquine, methotrexate, cyclosporine A, and retinoids.

Detailed description: Cicatricial alopecia, also known as scarring alopecia, refers to a group of rare chronic inflammatory hair disorders resulting in irreversible hair loss. Lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) are the most common forms of primary lymphocytic cicatricial alopecia, affecting predominantly postmenopausal women. These conditions lead to significant quality of life impairment due to their chronic nature and the lack of effective, standardized treatment protocols. The study aimed to address the gap in evidence-based treatment guidelines by investigating the effectiveness of various systemic therapies currently used in clinical practice. The retrospective cohort study reviewed medical records of patients diagnosed with LPP or FFA at the Department of Dermatology, Erasmus MC University Medical Center, from July 2016 to July 2022.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of LPP or FFA
* 18 years or older

Exclusion Criteria:

* Other forms of cicatricial alopecia than LPP or FFA

Primary outcomes:
measure: Treatment response
timeFrame: The time frame for evaluating treatment response varies per patient due to the retrospective nature of the study. Patients were treated and assessed at various intervals between July 2016 and July 2022.
Secondary outcomes:
measure: Reason for discontinuation
timeFrame: The time frame for evaluating reason for discontinuation varies per patient due to the retrospective nature of the study. Patients were treated and assessed at various intervals between July 2016 and July 2022.
Other outcomes:
Locations:
city: Rotterdam
country: Netherlands
facility: Erasmus MC
state: Zuid-Holland
Study officials:
affiliation: Erasmus Medical Center
name: DirkJan Hijnen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: